17-hydroxyprogesterone ester-containing oral compositions and related methods
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
1. A method of treating a pregnant female at risk of having a preterm birth, said method comprising administering to said pregnant female a pharmaceutical composition comprising a therapeutically effective amount of 17-hydroxyprogesterone caproate (17-HPC) and a pharmaceutically acceptable carrier comprising a lipophilic additive selected from benzyl benzoate, castor oil and mixtures thereof, said lipophilic additive comprising at least 50 weight/weight percent (w/w %) of said carrier and said pharmaceutical composition having 50 w/w% or less castor oil and 50 w/w % or less benzyl benzoate wherein said pharmaceutical composition when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5 w/w % sodium lauryl sulfate at 50 RPM at 37° C., releases at least 20% of said 17-HPC at 60 minutes with a proviso that said composition does not include benzyl alcohol, and wherein said pharmaceutical composition comprises at least one of a capsulized pharmaceutical composition and a tablet.
2. The method of claim 1 , wherein said pharmaceutical composition comprises a capsulized pharmaceutical composition.
3. The method of claim 1 , wherein said pharmaceutical composition comprises a tablet.
4. The method of claim 2 , wherein said capsule includes from about 30 mg to about 300 mg of 17-HPC.
5. The method of claim 3 , wherein the tablet includes from about 20 mg to about 800 mg of 17-HPC.
6. The method of claim 1 , wherein said pharmaceutical composition comprises a controlled release dosage form.
7. The method of claim 2 , wherein the ratio of the amount of 17-HPC in the composition to the fill volume of said capsule is from about 0.02 g/mL to about 0.8 g/mL.
8. The method of claim 1 , wherein said carrier includes a hydrophilic additive.
9. The method of claim 1 , wherein said carrier includes a lipophilic additive.
10. The method of claim 1 , wherein said carrier includes at least one hydrophilic additive and at least one lipophilic additive and wherein said pharmaceutical composition comprises a lipophilic additive to hydrophilic additive ratio of about 90:10 to about 1:99.
11. The method of claim 1 , wherein said pharmaceutical composition comprises from about 28 to about 48 w/w % benzyl benzoate.
12. The method of claim 1 , wherein said pharmaceutical composition comprises about 23 to about 25 w/w % castor oil.
13. The method of claim 1 , wherein said pharmaceutical composition comprises about 5 to about 30 w/w 17-HPC.
14. The method of claim 1 , wherein said pharmaceutical composition comprises about 25 w/w % 17-HPC.
15. The method of claim 1 , wherein said 17-HPC is fully solubilized.
16. A method of treating a pregnant female at risk of having a preterm birth, said method comprising administering to said pregnant female a pharmaceutical composition comprising a therapeutically effective amount of 17-HPC and a pharmaceutically acceptable carrier comprising a lipophilic additive selected from benzyl benzoate, castor oil and mixtures thereof, said lipophilic additive comprising at least 50 w/w % of the carrier and said pharmaceutical composition having 50 w/w % or less castor oil and 50 w/w % or less benzyl benzoate wherein said pharmaceutical composition is prepared by combining castor oil, benzyl benzoate and 17-HPC with the proviso that benzyl alcohol is not combined with the pharmaceutical composition.
17. The method of claim 16 , wherein said pharmaceutical composition comprises at least one of a capsulized pharmaceutical composition and a tablet.
18. The method of claim 17 , wherein said capsulized pharmaceutical composition comprises from about 30 mg to about 300 mg of 17-HPC, and wherein said tablet comprises from about 20 mg to about 800 mg of 17-HPC.
19. The method of claim 16 , wherein said pharmaceutical composition comprises a controlled release dosage form.